Since SPA and LM-2I function as potent ASS1 agonist in cancer cells with low ASS1 expression, it would be very interesting to test whether they also act as ASS1 activator in those nontumor diseases caused by ASS1 deficiency or down-regulation. Here, ASS1 is linked to cancer.